MYDA Advisors’s Arbutus Biopharma ABUS Stock Holding History

MYDA Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-60,000	Closed	-$61K	–	99
2020 Q1	$61K	Buy	+60,000	New	+$162K	0.04%	118

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MYDA Advisors's ABUS Position: Q1 2021 in Review

MYDA Advisors sold out of Arbutus Biopharma (ABUS) in Q1 2021, closing a stake of 30,000 shares — an estimated $107K sold.

MYDA Advisors first reported a position in ABUS in Q4 2020 and held it in 1 quarter. The position peaked at $107K in Q4 2020. 94 funds tracked by Wall St. Rank hold ABUS as of Q1 2021.

MYDA Advisors reported no remaining Arbutus Biopharma position as of Q1 2021 after selling out during the quarter.
MYDA Advisors sold 30,000 Arbutus Biopharma shares in Q1 2021, an estimated $107K.
MYDA Advisors first reported a position in Arbutus Biopharma in Q4 2020 and held it in 1 quarter.
MYDA Advisors's Arbutus Biopharma position peaked at $107K in Q4 2020.
94 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2021.

Based on MYDA Advisors's 13F filing for Q1 2021, filed 12 May 2021.